Hims Semaglutide & Wegovy: Complete Guide to GLP-1 Weight Loss Through Hims

Hims has become one of the largest telehealth providers for GLP-1 weight loss medications. Following a landmark partnership with Novo Nordisk in March 2026, Hims now offers both compounded semaglutide and FDA-approved Wegovy and Ozempic. Here is everything you need to know about getting semaglutide through Hims.

The Hims & Novo Nordisk Partnership (March 2026)

On March 9, 2026, Hims & Hers announced a strategic collaboration with Novo Nordisk, the maker of Ozempic and Wegovy. This partnership fundamentally changes the Hims weight loss offering by bringing FDA-approved GLP-1 medications onto the platform alongside compounded options.

Under the agreement, Hims will offer Ozempic (semaglutide) injections, Wegovy injections, and the newly approved oral Wegovy pill directly through its telehealth platform. The company also plans to continue offering compounded semaglutide on a limited basis for patients who qualify.

This partnership is significant because it addresses a core concern about telehealth GLP-1 providers: the quality and regulatory status of compounded medications. With FDA-approved options now available, patients can choose between cost-effective compounded semaglutide and clinically validated brand-name products.

How Hims Semaglutide Works

The Hims weight loss program follows a structured telehealth model. You start by completing an online health assessment covering your medical history, current medications, weight loss goals, and any contraindications. A licensed healthcare provider reviews your information and determines whether semaglutide is appropriate.

If approved, your provider prescribes semaglutide and your medication is shipped directly to your home. Hims provides ongoing support through its app, including dose escalation guidance, side effect management tips, and regular check-ins with your provider.

The entire process is completed online. There are no in-person visits required, making it accessible for patients who don't live near a semaglutide provider or who prefer the convenience of telehealth.

Medication Options on Hims

FDA-Approved Semaglutide (Wegovy & Ozempic)

Through the Novo Nordisk partnership, Hims now offers brand-name semaglutide for weight loss:

• Wegovy (injectable): FDA-approved specifically for chronic weight management. Dosed at 2.4 mg weekly after a 16-20 week dose escalation. Clinical trials showed approximately 15% mean body weight loss.
• Ozempic (injectable): FDA-approved for type 2 diabetes, widely prescribed off-label for weight loss. Maximum dose 2.0 mg weekly. Typically produces 10-14% weight loss.
• Wegovy pill (oral semaglutide 25 mg): The first oral GLP-1 for weight loss, approved by the FDA in late 2025 and launched in early January 2026. Taken once daily, it showed 16.6% mean weight loss in the OASIS 4 trial.

Compounded Semaglutide

Hims continues to offer compounded semaglutide on a limited basis. Compounded versions are pharmacy-prepared and are not FDA-approved. They may use semaglutide sodium or other salt forms rather than the base semaglutide used in brand products.

The FDA has taken enforcement action against mass-marketed compounded GLP-1 products in February 2026, warning that companies cannot claim compounded products are equivalent to FDA-approved drugs. Hims has adjusted its marketing and positioning accordingly, now emphasizing its FDA-approved options.

Hims Semaglutide Pricing Breakdown

Pricing varies based on whether you choose compounded or brand-name semaglutide:

The oral Wegovy pill at $149/month for cash-paying patients represents a significant price reduction compared to injectable options. This is particularly relevant for patients without insurance coverage for GLP-1 medications. For a detailed comparison of all semaglutide pricing options, see our semaglutide cost without insurance guide.

Who Qualifies for Semaglutide Through Hims?

Hims follows standard prescribing criteria for GLP-1 medications. You may be eligible if you meet one of the following:

• BMI of 30 or higher (obesity) without additional conditions required
• BMI of 27 or higher (overweight) with at least one weight-related comorbidity such as hypertension, type 2 diabetes, high cholesterol, or sleep apnea
• Type 2 diabetes requiring glycemic control (Ozempic indication)

Contraindications include personal or family history of medullary thyroid carcinoma, MEN2 syndrome, history of pancreatitis, pregnancy or breastfeeding, and severe gastrointestinal disease. Your Hims provider will screen for these during the consultation.

Compounded vs. Brand-Name Semaglutide: Key Differences

Understanding the distinction between compounded and brand-name semaglutide is critical for making an informed choice:

• Regulatory status: Brand-name Wegovy and Ozempic are FDA-approved with extensive clinical trial data. Compounded semaglutide is not FDA-approved and is technically only permitted in limited, patient-specific situations.
• Active ingredient: Brand products use semaglutide base. Some compounders use semaglutide sodium, which the FDA considers a different substance not listed in the FDA's approved drug products database.
• Quality assurance: Brand medications undergo rigorous manufacturing standards (cGMP). Compounded products vary by pharmacy and don't receive the same level of FDA oversight.
• Clinical evidence: All weight loss data (STEP trials, OASIS trials) comes from brand-name semaglutide. Compounded versions have not been tested in clinical trials.
• Cost: Compounded semaglutide is typically 50-80% cheaper than brand-name options without insurance.

For more on the legal status of compounded semaglutide in 2026, see our dedicated guide.

FDA Enforcement and What It Means for Hims

In February 2026, FDA Commissioner Martin Makary announced the agency would take decisive steps to restrict compounded GLP-1 products, specifically naming Hims & Hers among companies targeted. The FDA stated that mass-marketed compounded products cannot claim equivalence to FDA-approved drugs.

This regulatory pressure likely accelerated the Hims-Novo Nordisk partnership. By offering FDA-approved Wegovy and Ozempic, Hims positions itself as a compliant telehealth provider rather than a compounding-dependent business. The company has announced plans to scale down compounded semaglutide offerings while scaling up brand-name access.

For patients currently using compounded semaglutide through Hims, the transition to brand-name options may involve changes in cost, dosing, and formulation. Your provider can guide this transition. See our guide on the FDA peptide regulatory landscape for broader context.

The Oral Wegovy Pill on Hims

The FDA-approved oral Wegovy pill (semaglutide 25 mg once daily) represents a major expansion of access to GLP-1 weight loss treatment. For patients who are needle-averse or prefer a daily pill over weekly injections, this is a game-changer.

Key facts about oral Wegovy on Hims:

• Dosing: One pill daily, taken on an empty stomach with no more than 4 ounces of water, at least 30 minutes before eating
• Efficacy: 16.6% mean weight loss in the OASIS 4 trial, comparable to injectable Wegovy
• Price: Starting at $149/month for cash-paying patients; $25 or less with insurance co-pay
• Availability: Now broadly available across the US as of early 2026

Note that the oral pill contains SNAC (salcaprozate sodium), an absorption enhancer that helps semaglutide survive stomach acid. A February 2026 study from Adelaide University raised preliminary questions about SNAC's effects on gut bacteria, though these findings were in animal models and do not prove harm in humans. For details, see our oral semaglutide guide.

Common Side Effects and Management

Side effects of semaglutide are the same regardless of whether you get it through Hims or another provider. The most common include:

• Nausea: Affects 40-50% of patients, most common during dose escalation. Usually improves over 2-4 weeks at each dose. Eating smaller meals and avoiding high-fat foods helps.
• Diarrhea and constipation: GI effects are common early on. Staying hydrated and maintaining fiber intake can help.
• Decreased appetite: This is the intended mechanism of action. If appetite reduction is too severe, your provider may slow dose escalation.
• Fatigue: Some patients report tiredness during initial weeks. Adequate protein and hydration usually help.

For a comprehensive overview, see our guides on semaglutide side effects and managing Ozempic nausea.

Hims vs. Other GLP-1 Telehealth Providers

Hims is best for patients seeking the most affordable entry point, especially with the oral Wegovy pill at $149/month. For patients who want more comprehensive support including metabolic coaching and insurance handling, providers like Calibrate or Found may be worth the higher cost. For a broader comparison of options, see our guide on telehealth GLP-1 visits.

Who Should (and Shouldn't) Use Hims for Semaglutide

Hims is a good fit if you:

• Want affordable access to semaglutide without insurance barriers
• Prefer a fully online, no-appointment-needed experience
• Are comfortable self-managing your weight loss journey with app-based support
• Want the convenience of the oral Wegovy pill shipped to your door
• Don't have complex medical conditions requiring close monitoring

Consider other options if you:

• Need direct insurance billing for GLP-1 coverage
• Want live video consultations with dedicated physicians
• Have complex medical conditions (kidney disease, history of pancreatitis, thyroid concerns)
• Prefer comprehensive metabolic coaching and dietary guidance
• Want tirzepatide instead of semaglutide